Delays to Adjuvant Breast Cancer Radiotherapy Resulting from Oncotype Dx Testing in Patients with Low/Intermediate Recurrence Risk Scores

Purpose: Oncotype Dx is a 21 gene recurrence score assay that risk stratifies patients who have completed primary surgical treatment for breast cancer to low or intermediate (adjuvant chemotherapy not routinely recommended) versus high risk of recurrence (adjuvant chemotherapy recommended). 73% of patients tested are stratified to the low/intermediate risk of recurrence group [1]. However, a proportion of these patients may have delays to commencing adjuvant radiotherapy. The current median time to adjuvant radiotherapy following surgery is recorded as 60 days [2].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research